Exploring the clinical utility of Oncotype DX in ER+/HER2-, N0 and N1 breast cancer patients: Insights from a Romanian cohort

被引：0

作者：

Blidaru, A. ^{[1
]}

Zob, D. ^{[2
]}

Schenker, M. ^{[3
]}

Onisim, A. ^{[4
]}

Bodale, C. ^{[5
]}

Curca, R. ^{[6
]}

Negru, S. ^{[7
]}

Oprean, C. ^{[7
]}

Curescu, P. ^{[8
]}

Gafton, B. ^{[9
]}

Volovat, S. ^{[9
]}

Mihaila, R. ^{[2
]}

Filip, G. ^{[10
]}

Median, D. ^{[11
]}

Dediu, M. ^{[12
]}

Chetroiu, D. ^{[13
]}

Pantelimon, I. ^{[14
]}

Costovici, C. ^{[15
]}

Viisoreanu, C. G. ^{[16
]}

Titirez, V. ^{[17
]}

Mateescu, D. ^{[17
]}

Gal, C. ^{[17
]}

Vremes, G. ^{[18
]}

Stanculeanu, D. -L. ^{[1
]}

Tsoulos, N. ^{[19
]}

Kapetsis, G. ^{[19
]}

Giannoulakis, S. ^{[19
]}

Sires, A.

Chirnogea, A. ^{[20
]}

Maxim, A. -I. ^{[20
]}

Iorga, P. ^{[21
]}

Jinga, D. -C. ^{[22
]}

Nitipir, C. ^{[23
]}

机构：

[1] Alexandru Trestioreanu Inst, Bucharest, Romania

[2] Bucharest Oncol Inst, Bucharest, Romania

[3] St Nectarie Oncol Ctr, Craiova, Romania

[4] Medisprof Cluj Napoca, Cluj Napoca, Romania

[5] Amethyst Cluj Napoca, Cluj Napoca, Romania

[6] Elysee Alba Iulia, Alba Iulia, Romania

[7] OncoHelp Timisoara, Timisoara, Romania

[8] Timisoara Municipal Hosp, Timisoara, Romania

[9] Reg Inst Oncol Iasi, Iasi, Romania

[10] Ponderas Acad Hosp Regina Maria, Bucharest, Romania

[11] FILANTROPIA Clin Hosp Bucharest, Bucharest, Romania

[12] Provita Med Grp, Bucharest, Romania

[13] Bucharest Univ Emergency Hosp, Bucharest, Romania

[14] Clin Hosp Dr Ion Cantacuzino, Bucharest, Romania

[15] CMDTAMP Bucharest, Bucharest, Romania

[16] MedLife Breast Inst, Bucharest, Romania

[17] Euroclin Hosp Regina Maria, Bucharest, Romania

[18] MedLife Titan Hosp, Bucharest, Romania

[19] Genekor SA, Athens, Greece

[20] Fundeni Clin Inst Bucharest, Bucharest, Romania

[21] Clin Emergency Hosp Bucharest, Bucharest, Romania

[22] Neolife Clin Bucharest, Bucharest, Romania

[23] Agrippa Ionescu Hosp, Bucharest, Romania

来源：

BREAST | 2025年 / 80卷

关键词：

D O I：

10.1016/j.breast.2025.103934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P051

引用

页数：2

共 50 条

[1] Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer
Iosifidou, R.
Xepapadakis, G.
Venizelos, V.
Markopoulos, C.
Papazisis, K.
Tsoulos, N.
Kapetsis, G.
Giannoulakis, S.
Paraskeva, M.
Kaparelou, M.
Lainakis, G.
Fotarelli, A.
Pavlidou, F.
Fountzilas, E.
Saloustros, E.
Karageorgopoulou, S.
Triantafillidou, S.
Intzes, S.
Koinis, F.
BREAST, 2025, 80
[2] Multi-gene assay "Curebest 95GC" for recurrence prediction for ER+/HER2-/n0 breast cancer patients
Naoi, Yasuto
Noguchi, Shinzaburo
ANNALS OF ONCOLOGY, 2016, 27
[3] Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2-Breast Cancer
Amlicke, Maire J.
Park, Jihye
Agala, Chris B.
Casey, Dana L.
Ray, Emily M.
Downs-Canner, Stephanie M.
Spanheimer, Philip M.
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (12) : 7662 - 7669
[4] Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2− Breast Cancer
Maire J. Amlicke
Jihye Park
Chris B. Agala
Dana L. Casey
Emily M. Ray
Stephanie M. Downs-Canner
Philip M. Spanheimer
Annals of Surgical Oncology, 2022, 29 : 7662 - 7669
[5] Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2-Breast Cancer
Song, Ran
Lee, Dong-Eun
Lee, Eun-Gyeong
Lee, Seeyoun
Kang, Han-Sung
Han, Jai Hong
Lee, Keun Seok
Sim, Sung Hoon
Chae, Heejung
Kwon, Youngmee
Woo, Jaeyeon
Jung, So-Youn
CANCERS, 2023, 15 (18)
[6] Using the National Cancer Data Base (NCDB) and Oncotype DX data to predict adjuvant therapy effect on overall survival (OS) of N0 & N1 breast cancer patients.
Orucevic, Amila
Robert, Heidel
Bell, John Lawrence
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] The Correlation of Magee Equations™ and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
Soran, Atilla
Tane, Kaori
Sezgin, EFe
Bhargava, Rohit
EUROPEAN JOURNAL OF BREAST HEALTH, 2020, 16 (02) : 117 - 123
[8] Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
Stemmer, Salomon M.
Steiner, Mariana
Rizel, Shulamith
Ben-Baruch, Noa
Uziely, Beatrice
Jakubowski, Debbie M.
Baron, Julie
Shak, Steven
Soussan-Gutman, Lior
Bareket-Samish, Avital
Fried, Georgeta
Rosengarten, Ora
Itay, Amit
Nisenbaum, Bella
Katz, Daniela
Leviov, Michelle
Tokar, Margarita
Liebermann, Nicky
Geffen, David B.
NPJ BREAST CANCER, 2019, 5 (1)
[9] Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
Salomon M. Stemmer
Mariana Steiner
Shulamith Rizel
Noa Ben-Baruch
Beatrice Uziely
Debbie M. Jakubowski
Julie Baron
Steven Shak
Lior Soussan-Gutman
Avital Bareket-Samish
Georgeta Fried
Ora Rosengarten
Amit Itay
Bella Nisenbaum
Daniela Katz
Michelle Leviov
Margarita Tokar
Nicky Liebermann
David B. Geffen
npj Breast Cancer, 5
[10] Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
Shuai Li
Jiayi Wu
Ou Huang
Jianrong He
Li Zhu
Weiguo Chen
Yafen Li
Xiaosong Chen
Kunwei Shen
BMC Cancer, 21

← 1 2 3 4 5 →